Ignite Creation Date:
2024-05-06 @ 1:46 AM
Last Modification Date:
2024-10-26 @ 11:09 AM
Study NCT ID:
NCT01890876
Status:
COMPLETED
Last Update Posted:
2019-01-22
First Post:
2013-06-27
Brief Title:
Altitude Exercise and Glucose Metabolism in Pre-diabetic Men
Sponsor:
Universitaet Innsbruck
Organization:
Universitaet Innsbruck
Study Overview
Official Title:
Altitude-dependent Effects of Concentric and Eccentric Exercise on Glucose Metabolism in Pre-diabetic Men
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Concentric CE and eccentric EE exercises may differently affect glucose metabolism which may be additionally modified when exercises are performed in hypoxia eg at moderate 1500 - 2500 m or high 2500 - 3500 m altitudes However data on the effects of glucose metabolism due to CE and EE in hypoxia are scarce but would be of utmost importance considering the increasing number of persons suffering from impaired glucose tolerance or diabetes and the unique opportunities provided by the mountainous regions of the Alps to perform CE eg uphill hiking and EE downhill hiking downhill skiing at altitude between 1500 - 3500 m Metabolic responses to exercise may be largely mediated by interleukin 6 IL-6 which is predominantly derived from the contracting limbs and may support the maintenance of metabolic homeostasis during exercise In addition IL-6 is elevated with acute and chronic altitude exposure at least partly mediated via adrenergic stimulation Thus the type of exercise as well as hypoxia may contribute to IL-6 elevations and differences in serum IL-6 concentrations might help to explain distinctions between responses of glucose metabolism to CE and EE at low and moderate to high altitude
32 male subjects suffering from pre-diabetes will be randomly assigned to a downhill EE or uphill CE walking group performing 9 sessions at low altitude 860 - 1360 m and 9 sessions at moderate to high altitude 2000 - 2500 m Between normoxic and hypoxic condition will be a break of approximately 12 month Measurements of glucose metabolism IL-6 plasma concentration will be performed pre mid day 5 and post intervention Moreover anthropometric strength and exercise capacity characteristics will be performed pre and post intervention
We hypothesize that EE in hypoxia is more effective in the modulation of glycemic control in pre-diabetic men than CE in hypoxia as well as EE and CE in normoxia It is suggested that effects on glucose metabolism are associated with changes in plasma IL-6 concentrations EE in hypoxia is expected to result in a more persistent rise of plasma IL-6 concentration than CE in hypoxia and in normoxia and to a more pronounced rise in plasma IL-6 than EE in normoxia
32 male subjects suffering from pre-diabetes will be randomly assigned to a downhill EE or uphill CE walking group performing 9 sessions at low altitude 860 - 1360 m and 9 sessions at moderate to high altitude 2000 - 2500 m Between normoxic and hypoxic condition will be a break of approximately 12 month Measurements of glucose metabolism IL-6 plasma concentration will be performed pre mid day 5 and post intervention Moreover anthropometric strength and exercise capacity characteristics will be performed pre and post intervention
We hypothesize that EE in hypoxia is more effective in the modulation of glycemic control in pre-diabetic men than CE in hypoxia as well as EE and CE in normoxia It is suggested that effects on glucose metabolism are associated with changes in plasma IL-6 concentrations EE in hypoxia is expected to result in a more persistent rise of plasma IL-6 concentration than CE in hypoxia and in normoxia and to a more pronounced rise in plasma IL-6 than EE in normoxia
Detailed Description:
Not desired
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None